CNTB•benzinga•
Connect Biopharma Announces Reduction in Annualized Exacerbations With Rademikibart in Eosinophilic Driven, Type 2 Asthma Oral Presentations And Improvement In Lung Function with Rademikibart In Eosinophilic Driven, Type 2 Asthma In Two Oral Presentation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga